Advertisement
Organisation › Details
Boehringer Ingelheim Animal Health, Veterinary Vaccine Manufacturing Plant in Taizhou, China
Boehringer Ingelheim began building a world-class veterinary vaccine manufacturing plant in Taizhou in 2013, thus demonstrating its commitment to being ’in China, for China’. The first phase of the plant, with a total investment of 85 million euros, was completed in 2016. The plant’s manufacturing facilities, production process, quality control system and staffing meet Good Manufacturing Practice (GMP) standards in the EU; in December 2017, the Taizhou plant obtained GMP certification from the Ministry of Agriculture of China. The annual production capacity of the Taizhou plant reaches 125 million doses, with Ingelvac® PRRS MLV as the first product made locally. *
Start | 2019-01-24 existent | |
Industry | animal vaccine | |
Industry 2 | Ingelvac® PRRS MLV swine vaccine | |
Region | Taizhou, Jiangsu | |
Country | China | |
City | n. a. Taizhou, Jiangsu province | |
Address record changed: 2019-02-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Boehringer Ingelheim. (1/24/19). "Press Release: Boehringer Ingelheim Launches First Veterinary Vaccines Produced in China". Ingelheim. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Boehringer Ingelheim Animal Health, Veterinary Vaccine Manufacturing Plant in Taizhou, China
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top